{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+ritonavir&page=2", "query": { "intervention": "Placebo for ritonavir", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 38, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+ritonavir&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+for+ritonavir&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T23:43:35.704Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00244712", "title": "Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "emtricitabine/tenofovir", "type": "DRUG" }, { "name": "abacavir/lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 688, "start_date": "2005-07", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2010-06-08", "last_synced_at": "2026-10-04T23:43:35.704Z", "location_count": 72, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00244712" }, { "nct_id": "NCT01278134", "title": "A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus placebo", "type": "DRUG" }, { "name": "RO5024048", "type": "DRUG" }, { "name": "danoprevir", "type": "DRUG" }, { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2011-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-10-04T23:43:35.704Z", "location_count": 18, "location_summary": "La Jolla, California • Sacramento, California • Orlando, Florida + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01278134" }, { "nct_id": "NCT05545319", "title": "A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)", "Coronavirus Disease 2019 (COVID-19)", "Immunocompromised", "Hospitalization", "Child, Hospitalized" ], "interventions": [ { "name": "Nirmatrelvir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Placebo for nirmatrelvir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2022-12-13", "completion_date": "2024-01-06", "has_results": false, "last_update_posted_date": "2023-03-01", "last_synced_at": "2026-10-04T23:43:35.704Z", "location_count": 2, "location_summary": "Cooperstown, New York • New York, New York", "locations": [ { "city": "Cooperstown", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05545319" }, { "nct_id": "NCT07597902", "title": "SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Post-acute Sequelae of COVID-19", "Long COVID" ], "interventions": [ { "name": "Valacyclovir", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Paxlovid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 150, "start_date": "2026-06-01", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-04T23:43:35.704Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07597902" }, { "nct_id": "NCT01802918", "title": "Single Dose Escalation Study of GSK2838232 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK2838232", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 17, "start_date": "2013-02-18", "completion_date": "2013-11-21", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-04T23:43:35.704Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802918" }, { "nct_id": "NCT02289495", "title": "A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK2838232", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 24, "start_date": "2014-11-18", "completion_date": "2015-06-27", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-04T23:43:35.704Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289495" }, { "nct_id": "NCT03719313", "title": "Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis Delta Virus" ], "interventions": [ { "name": "Lonafarnib", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "PEG IFN-alfa-2a", "type": "DRUG" }, { "name": "Placebo Lonafarnib", "type": "DRUG" }, { "name": "Placebo Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eiger BioPharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2018-12-01", "completion_date": "2023-03-24", "has_results": false, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-04T23:43:35.704Z", "location_count": 18, "location_summary": "Fresno, California • Los Angeles, California • Palo Alto, California + 12 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719313" }, { "nct_id": "NCT00720590", "title": "Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endothelial Dysfunction" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Lopinavir/ritonavir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 30, "start_date": "2003-11", "completion_date": "2006-10", "has_results": false, "last_update_posted_date": "2017-10-25", "last_synced_at": "2026-10-04T23:43:35.704Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720590" }, { "nct_id": "NCT05595369", "title": "RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Long Covid19" ], "interventions": [ { "name": "Experimental: Paxlovid 25 day dosing", "type": "DRUG" }, { "name": "Experimental: Paxlovid 15 day dosing", "type": "DRUG" }, { "name": "Placebo Comparator: Control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kanecia Obie Zimmerman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 963, "start_date": "2023-07-26", "completion_date": "2025-03-13", "has_results": true, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-10-04T23:43:35.704Z", "location_count": 68, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05595369" }, { "nct_id": "NCT01400412", "title": "Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Emtricitabine", "type": "DRUG" }, { "name": "Placebo for Tenofovir disoproxil fumarate", "type": "DRUG" }, { "name": "Placebo for Maraviroc", "type": "DRUG" }, { "name": "Maraviroc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 262, "start_date": "2012-01-17", "completion_date": "2014-06-30", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-10-04T23:43:35.704Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01400412" } ] }